These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 18075281)
21. Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice. Starenki D; Singh NK; Jensen DR; Peterson FC; Park JI Cancer Lett; 2013 Oct; 339(1):144-51. PubMed ID: 23856028 [TBL] [Abstract][Full Text] [Related]
22. RET oncogene mutations in medullary thyroid carcinoma in Mexican families. González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374 [TBL] [Abstract][Full Text] [Related]
23. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Ezzat S; Huang P; Dackiw A; Asa SL Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206 [TBL] [Abstract][Full Text] [Related]
24. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. Strock CJ; Park JI; Rosen DM; Ruggeri B; Denmeade SR; Ball DW; Nelkin BD J Clin Endocrinol Metab; 2006 Jan; 91(1):79-84. PubMed ID: 16263812 [TBL] [Abstract][Full Text] [Related]
25. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225 [TBL] [Abstract][Full Text] [Related]
26. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464 [TBL] [Abstract][Full Text] [Related]
27. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Acton DS; Velthuyzen D; Lips CJ; Höppener JW Oncogene; 2000 Jun; 19(27):3121-5. PubMed ID: 10871866 [TBL] [Abstract][Full Text] [Related]
28. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. Gild ML; Landa I; Ryder M; Ghossein RA; Knauf JA; Fagin JA Endocr Relat Cancer; 2013 Oct; 20(5):659-67. PubMed ID: 23828865 [TBL] [Abstract][Full Text] [Related]
29. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation. Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037 [TBL] [Abstract][Full Text] [Related]
30. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Hong D; Ye L; Gagel R; Chintala L; El Naggar AK; Wright J; Kurzrock R Mol Cancer Ther; 2008 May; 7(5):1001-6. PubMed ID: 18445656 [TBL] [Abstract][Full Text] [Related]
31. Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation. González-Yebra B; Medrano ME; Mantilla A; Palma V; Colin C; Hernández DM; Tapia J; Dawson B; Salcedo M Endocr Pathol; 2003; 14(1):71-80. PubMed ID: 12746565 [TBL] [Abstract][Full Text] [Related]
32. Medullary Thyroid Carcinoma Associated with Germline RET Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Cohen MS; Hussain HB; Moley JF Surgery; 2002 Dec; 132(6):960-6; discussion 966-7. PubMed ID: 12490842 [TBL] [Abstract][Full Text] [Related]
34. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Ludwig L; Kessler H; Wagner M; Hoang-Vu C; Dralle H; Adler G; Böhm BO; Schmid RM Cancer Res; 2001 Jun; 61(11):4526-35. PubMed ID: 11389085 [TBL] [Abstract][Full Text] [Related]
35. CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Corrado A; Fioravanti A; Sartini S; Orlandi P; Piaggi S; Corti A; Materazzi G; Galleri D; Ulisse S; Fontanini G; Danesi R; Da Settimo F; Miccoli P Mol Cell Endocrinol; 2014 Aug; 393(1-2):56-64. PubMed ID: 24931161 [TBL] [Abstract][Full Text] [Related]
36. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668 [TBL] [Abstract][Full Text] [Related]
37. RET signals through focal adhesion kinase in medullary thyroid cancer cells. Panta GR; Nwariaku F; Kim LT Surgery; 2004 Dec; 136(6):1212-7. PubMed ID: 15657578 [TBL] [Abstract][Full Text] [Related]